Interactions discovered in cells insulating nerve pathways

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurological diseases may occur as a result. Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have succeeded in demonstrating a complex interaction within Schwann cells which plays an important role for correct cell maturation.

Insulation and nutrients

For years, Dr. Franziska Fröb and Dr. Michael Wegner have devoted most of their time to researching one particular type of cell in the human body: Schwann cells. Similarly to insulation on electric cables, these cells form a sheath around the nerve fibres in the peripheral nervous system which connect nerve cells to muscle cells and the surrounding area and conduct impulses. If this protective layer, known as the myelin sheath, is damaged, the exchange of information becomes slower, incorrect, or ceases entirely. Nerve fibres and the corresponding nerve cells may die completely, as the Schwann cells also provide them with nutrients. The consequences for patients are pain, numbness, muscular atrophy or problems with moving hands and feet correctly.

Improved understanding of networks

Researchers Dr. Fröb and Prof. Wegner, Chair of Biochemistry and Pathobiochemistry at FAU, hope that they will one day be able to help people suffering from diseases such as diabetic neuropathy, Charcot-Marie-Tooth disease or Guillain-Barré syndrome. However, there is still a long way to go. After more than 25 years of research on this type of cell, most of the proteins and protein complexes which have a role to play in the development and maturation of Schwann cells have been identified. However, the proteins interact with each other as well. Research into how the various components within this regulatory network interact is only just beginning. 'We will only be able to consider possible therapies once we have gained a better understanding of the networks,' Prof. Dr. Michael Wegner explains the current state of research.

The FAU working group has now succeeded in deciphering one of these complex links. Research has focused on a protein named Ep400, which the team has only recently discovered in Schwann cells. Together with other proteins, this protein acts within Schwann cells to ensure that DNA is packaged correctly and marked accordingly. Packaging is immensely important in order to transport genetic information to the cell nucleus as compactly as possible. Marking allows the required information to be found and read. In their experiments, the scientists deleted the protein from the Schwann cells. Thereafter, the mechanism for creating cells did not complete correctly and overlapped the maturation mechanism which would normally follow, meaning that certain proteins which were no longer required continued to be created without restriction, whilst other proteins which were required were no longer produced in sufficient quantities. As a result, the myelin sheaths of the Schwann cells were deformed. They were too thin and short, and the protective sheath of the nerve fibres was defective as a result. When the scientists deleted a further protein named Tfap2a which is normally regulated by Ep400 and which had been continued to be produced, there was a marked reduction in defects.

"We are, of course, pleased that we have made such a significant step forward in understanding the complex interdependencies within the Schwann cells," explains Prof. Wegner. "Our results indicate that DNA structural changes induced by proteins such as Ep400 are extremely important and may also be useful in future to develop therapies for peripheral neuropathy."

Franziska Fröb, Elisabeth Sock, Ernst R Tamm, Anna-Lena Saur, Simone Hillgärtner, Trevor J Williams, Toshihiro Fujii, Rikiro Fukunaga, Michael Wegner.
Ep400 deficiency in Schwann cells causes persistent expression of early developmental regulators and peripheral neuropathy.
Nature Communicationsvolume 10, Article number: 2361 (2019). doi: 10.1038/s41467-019-10287-w.

Most Popular Now

A step closer to cancer precision medicine

Researchers from the Faculty of Medicine and the Institute for Molecular Medicine (FIMM) at the University of Helsinki have developed a computational model, Combined Esse...

Artificial Intelligence algorithm can learn the la…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of resea...

Amgen completes acquisition of Otezla® (apremilast…

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for mo...

Bristol-Myers Squibb completes acquisition of Celg…

Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all governmen...

Amgen and the Duke Clinical Research Institute ann…

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Inves...

Statins not associated with memory or cognition de…

Given consumer concern that statins may be associated with memory or cognitive decline, a new study published today in the Journal of the American College of Cardiology m...

Novartis announces new strategy to provide innovat…

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest unders...

New advances in the treatment of advanced lung can…

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic an...

FDA grants priority review to Roche’s risdiplam fo…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for ...

A protein tag to study the immune system

Researchers from VIB-UGent Center for Medical Biotechnology, University of Iowa (USA) and other collaborators, developed a novel approach to better understand a basic def...

Bayer and Dewpoint Therapeutics partner to researc…

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to ...

Pharmacist-led interventions may help prevent card…

With their expertise in the safe and effective use of medications, pharmacists can help in the management of chronic diseases. A review and analysis published in the Brit...